Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
New Ray Medicine International Holding Ltd. ( (HK:6108) ) just unveiled an announcement.
New Ray Medicine International Holding Ltd. has issued a profit warning, indicating an expected loss of at least HK$30 million for the fiscal year ending December 31, 2024, compared to a loss of approximately HK$22.2 million in the previous year. The increase in loss is mainly attributed to an impairment loss on slow-moving inventories nearing expiry, partially offset by a fair value gain on financial assets. The company is still finalizing its financial statements, and the figures are subject to change. Stakeholders are advised to exercise caution when dealing with the company’s securities.
More about New Ray Medicine International Holding Ltd.
New Ray Medicine International Holding Ltd. is a company incorporated in Bermuda, operating in the pharmaceutical industry. It focuses on the distribution and trading of pharmaceutical products and healthcare-related services, primarily in the Hong Kong market.
YTD Price Performance: 10.0%
Average Trading Volume: 2,085,417
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: HK$73.56M
For a thorough assessment of 6108 stock, go to TipRanks’ Stock Analysis page.